These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1011 related articles for article (PubMed ID: 26276009)

  • 21. Expansion of EBNA1-specific effector T cells in posttransplantation lymphoproliferative disorders.
    Jones K; Nourse JP; Morrison L; Nguyen-Van D; Moss DJ; Burrows SR; Gandhi MK
    Blood; 2010 Sep; 116(13):2245-52. PubMed ID: 20562330
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dual stimulation of Epstein-Barr Virus (EBV)-specific CD4+- and CD8+-T-cell responses by a chimeric antigen construct: potential therapeutic vaccine for EBV-positive nasopharyngeal carcinoma.
    Taylor GS; Haigh TA; Gudgeon NH; Phelps RJ; Lee SP; Steven NM; Rickinson AB
    J Virol; 2004 Jan; 78(2):768-78. PubMed ID: 14694109
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Increased T-cell responses to Epstein-Barr virus with high viral load in patients with Epstein-Barr virus-positive diffuse large B-cell lymphoma.
    Morishima S; Nakamura S; Yamamoto K; Miyauchi H; Kagami Y; Kinoshita T; Onoda H; Yatabe Y; Ito M; Miyamura K; Nagai H; Moritani S; Sugiura I; Tsushita K; Mihara H; Ohbayashi K; Iba S; Emi N; Okamoto M; Iwata S; Kimura H; Kuzushima K; Morishima Y
    Leuk Lymphoma; 2015 Apr; 56(4):1072-8. PubMed ID: 24975317
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Generation of EBV-specific T cells for adoptive immunotherapy: a novel protocol using formalin-fixed stimulator cells to increase biosafety.
    Hammer MH; Brestrich G; Mittenzweig A; Roemhild A; Zwinger S; Subklewe M; Beier C; Kurtz A; Babel N; Volk HD; Reinke P
    J Immunother; 2007; 30(8):817-24. PubMed ID: 18049333
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CD4+ T cell-induced differentiation of EBV-transformed lymphoblastoid cells is associated with diminished recognition by EBV-specific CD8+ cytotoxic T cells.
    Khanolkar A; Fu Z; Underwood LJ; Bondurant KL; Rochford R; Cannon MJ
    J Immunol; 2003 Mar; 170(6):3187-94. PubMed ID: 12626577
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunodominance of lytic cycle antigens in Epstein-Barr virus-specific CD4+ T cell preparations for therapy.
    Adhikary D; Behrends U; Boerschmann H; Pfünder A; Burdach S; Moosmann A; Witter K; Bornkamm GW; Mautner J
    PLoS One; 2007 Jul; 2(7):e583. PubMed ID: 17611619
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dendritic cells cross-present latency gene products from Epstein-Barr virus-transformed B cells and expand tumor-reactive CD8(+) killer T cells.
    Subklewe M; Paludan C; Tsang ML; Mahnke K; Steinman RM; Münz C
    J Exp Med; 2001 Feb; 193(3):405-11. PubMed ID: 11157061
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cytolytic CD4(+)-T-cell clones reactive to EBNA1 inhibit Epstein-Barr virus-induced B-cell proliferation.
    Nikiforow S; Bottomly K; Miller G; Münz C
    J Virol; 2003 Nov; 77(22):12088-104. PubMed ID: 14581546
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Differential immunogenicity of Epstein-Barr virus latent-cycle proteins for human CD4(+) T-helper 1 responses.
    Leen A; Meij P; Redchenko I; Middeldorp J; Bloemena E; Rickinson A; Blake N
    J Virol; 2001 Sep; 75(18):8649-59. PubMed ID: 11507210
    [TBL] [Abstract][Full Text] [Related]  

  • 30. First Days in the Life of Naive Human B Lymphocytes Infected with Epstein-Barr Virus.
    Pich D; Mrozek-Gorska P; Bouvet M; Sugimoto A; Akidil E; Grundhoff A; Hamperl S; Ling PD; Hammerschmidt W
    mBio; 2019 Sep; 10(5):. PubMed ID: 31530670
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of suitable target antigens and immunoassays for high-accuracy immune monitoring of cytomegalovirus and Epstein-Barr virus-specific T cells as targets of interest in immunotherapeutic approaches.
    Tischer S; Dieks D; Sukdolak C; Bunse C; Figueiredo C; Immenschuh S; Borchers S; Stripecke R; Maecker-Kolhoff B; Blasczyk R; Eiz-Vesper B
    J Immunol Methods; 2014 Jun; 408():101-13. PubMed ID: 24877879
    [TBL] [Abstract][Full Text] [Related]  

  • 32. B cells immortalized by a mini-Epstein-Barr virus encoding a foreign antigen efficiently reactivate specific cytotoxic T cells.
    Moosmann A; Khan N; Cobbold M; Zentz C; Delecluse HJ; Hollweck G; Hislop AD; Blake NW; Croom-Carter D; Wollenberg B; Moss PA; Zeidler R; Rickinson AB; Hammerschmidt W
    Blood; 2002 Sep; 100(5):1755-64. PubMed ID: 12176897
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Regulation and dysregulation of Epstein-Barr virus latency: implications for the development of autoimmune diseases.
    Niller HH; Wolf H; Minarovits J
    Autoimmunity; 2008 May; 41(4):298-328. PubMed ID: 18432410
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cytotoxic CD4+ T cell responses to EBV contrast with CD8 responses in breadth of lytic cycle antigen choice and in lytic cycle recognition.
    Long HM; Leese AM; Chagoury OL; Connerty SR; Quarcoopome J; Quinn LL; Shannon-Lowe C; Rickinson AB
    J Immunol; 2011 Jul; 187(1):92-101. PubMed ID: 21622860
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Increased frequency and broadened specificity of latent EBV nuclear antigen-1-specific T cells in multiple sclerosis.
    Lünemann JD; Edwards N; Muraro PA; Hayashi S; Cohen JI; Münz C; Martin R
    Brain; 2006 Jun; 129(Pt 6):1493-506. PubMed ID: 16569670
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Recognition of Epstein-Barr virus-associated gastric carcinoma cells by cytotoxic T lymphocytes induced in vitro with autologous lymphoblastoid cell line and LMP2-derived, HLA-A24-restricted 9-mer peptide.
    Okugawa K; Itoh T; Kawashima I; Takesako K; Mazda O; Nukaya I; Yano Y; Yamamoto Y; Yamagishi H; Ueda Y
    Oncol Rep; 2004 Oct; 12(4):725-31. PubMed ID: 15375491
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Defining the expression hierarchy of latent T-cell epitopes in Epstein-Barr virus infection with TCR-like antibodies.
    Sim AC; Too CT; Oo MZ; Lai J; Eio MY; Song Z; Srinivasan N; Tan DA; Pang SW; Gan SU; Lee KO; Loh TK; Chen J; Chan SH; MacAry PA
    Sci Rep; 2013 Nov; 3():3232. PubMed ID: 24240815
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cyclical expression of EBV latent membrane protein 1 in EBV-transformed B cells underpins heterogeneity of epitope presentation and CD8+ T cell recognition.
    Brooks JM; Lee SP; Leese AM; Thomas WA; Rowe M; Rickinson AB
    J Immunol; 2009 Feb; 182(4):1919-28. PubMed ID: 19201845
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CD4+ T-cell effectors inhibit Epstein-Barr virus-induced B-cell proliferation.
    Nikiforow S; Bottomly K; Miller G
    J Virol; 2001 Apr; 75(8):3740-52. PubMed ID: 11264363
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Acquisition of polyfunctionality by Epstein-Barr virus-specific CD8+ T cells correlates with increased resistance to galectin-1-mediated suppression.
    Smith C; Beagley L; Khanna R
    J Virol; 2009 Jun; 83(12):6192-8. PubMed ID: 19357166
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 51.